98%
921
2 minutes
20
Introduction: A substantial proportion of patients with chronic coronary syndromes suffer from angina even after medical treatment and revascularization. Coronary microvascular dysfunction (CMD) is discussed as a potential mechanism.
Aim: To assess angina status in patients with chronic coronary syndromes undergoing functional assessment of coronary circulation regarding the presence of coronary microcirculatory dysfunction.
Material And Methods: The study included 101 consecutive patients referred for coronary angiography requiring functional stenosis assessment, with median age of 66 years, 74% male, diagnosed or treated for dyslipidemia (91%) and diabetes type 2 (42%), 20% with a history of prior non-ST myocardial infarction. Fractional flow reserve (FFR), coronary flow reserve (CFR), resistive reserve ratio (RRR), and index of microcirculatory resistance (IMR) were measured. The diagnosis of CMD was defined by either IMR ≥ 25 units or CFR ≤ 2.0 in case of no significant stenosis. A change of one CCS class over 24 months follow-up was considered clinically significant.
Results: In patients without CMD diagnosis, there was a significant decrease in angina intensity ( < 0.001). Lack of angina improvement was associated with lower median RRR (2.30 (1.70, 3.30) vs. 3.05 (2.08, 4.10), = 0.004) and lower median CFR (1.90 (1.40, 2.50) vs. 2.30 (IQR: 1.60, 3.00), = 0.021), as compared to patients with angina improvement.
Conclusions: The presence of CMD is a risk factor for no angina improvement. Impaired coronary resistive reserve ratio and lower microvascular reactivity may be one of the pathomechanisms leading to the lack of angina improvement in patients with chronic coronary syndromes.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10767557 | PMC |
http://dx.doi.org/10.5114/aic.2023.133806 | DOI Listing |
Pain Manag
September 2025
Pain Management Unit, Hospital Universitario Quirónsalud Madrid, Madrid, Spain.
Aims: The aim of this observational study is to describe the use of epiduroscopy to decrease the enlargement of the ligamentum flavum (LF) in patients with spinal stenosis, as well as the selection of the appropriate patient and the safety measures that enhance procedural success.
Materials & Methods: We introduce the patient selection protocol, define the appropriate indication and the safety measures to use the epiduroscopy as a tool to decrease the size of the LF and increase space, reducing possible complications.
Results: Among patients included in the study, there were no cases of access difficulty or coccydynia, and one case of urinary incontinence occurred in a patient with Schizas grade D (very severe) stenosis.
Nephrol Dial Transplant
September 2025
Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Background: We investigated circulating protein profiles and molecular pathways among various chronic kidney disease (CKD) etiologies to study its underlying molecular heterogeneity.
Methods: We conducted a proteomic biomarker analysis in the DAPA-CKD trial recruiting adults with and without type 2 diabetes with an eGFR of 25 to 75 mL/min/1.73m2 and a UACR of 200 to 5000 mg/g.
Clin J Am Soc Nephrol
September 2025
Temerty Faculty of Medicine, University of Toronto, Toronto, Canada.
Oncologist
September 2025
Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Background: Belzutifan is a HIF-2ɑ inhibitor approved for the treatment of tumors in von Hippel-Lindau (VHL) syndrome and sporadic metastatic clear cell renal cell carcinoma (spRCC) in the refractory setting. The efficacy and side effects of belzutifan are well-documented from clinical trials, however, real-world data examining the incidence and management of adverse events (AEs) are lacking. Our study aims to describe the AE profiles of belzutifan in spRCC and VHL populations.
View Article and Find Full Text PDFCell Mol Biol (Noisy-le-grand)
September 2025
University Sousse, Faculty of Medicine "Ibn El-Jazzar", Department of Medical Genetics, Sousse, Tunisia.
The global epidemic of overweight and obesity is closely linked to the development of chronic kidney disease (CKD), with extremely obese individuals facing a particularly high risk. This study aimed to assess the relationship between lipid profile levels, SIRT1 expression, and RNA-34a-5P in the regulation of blood lipid levels among severely obese individuals with renal diseases. Conducted over six months in three specialized hospitals, the study included 100 participants divided into two groups: 50 obese individuals with renal diseases and 50 obese controls without renal problems.
View Article and Find Full Text PDF